A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD)
Latest Information Update: 28 Nov 2022
At a glance
- Drugs Bocidelpar (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 23 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 24 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2021 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.